Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0V9WF
|
|||
| Former ID |
DAP001395
|
|||
| Drug Name |
Lestaurtinib
|
|||
| Synonyms |
A 1544750; CEP 701; KT 5555; KT5555; SP 924; CEP-701; KT-5555; SPM-924; Lestaurtinib (USAN/INN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Approved (orphan drug) | [1], [2] | |
| Myeloid leukaemia [ICD-11: 2B33.1; ICD-9: 208.9] | Phase 3 | [1], [2] | ||
| Psoriasis vulgaris [ICD-11: EA90; ICD-9: 696] | Phase 2/3 | [1], [3], [4] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Cephalon; Kyowa Hakko Kogyo
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H21N3O4
|
|||
| Canonical SMILES |
CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O
|
|||
| InChI |
1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1
|
|||
| InChIKey |
UIARLYUEJFELEN-LROUJFHJSA-N
|
|||
| CAS Number |
CAS 111358-88-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14881395, 26683764, 29306097, 47206529, 50113274, 51950713, 57341827, 71821285, 91614175, 92721422, 103722924, 104162421, 124893551, 124893552, 124893553, 126619159, 126644891, 134338603, 135083872, 135698729, 137237684, 137267229, 141704182, 144206186, 162012051, 162187603, 163125761, 164228175, 164761562, 172087004, 177749083, 178102300, 179149589, 198961101, 204370206, 223654877, 227838931, 241376436, 248732980, 249815159, 252157256, 252215690
|
|||
| ChEBI ID |
CHEBI:91471
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fms-like tyrosine kinase 3 (FLT-3) | Target Info | Modulator | [3], [4] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Hematopoietic cell lineage | ||||
| Pathways in cancer | ||||
| Transcriptional misregulation in cancer | ||||
| Acute myeloid leukemia | ||||
| Central carbon metabolism in cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5672). | |||
| REF 2 | Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63. | |||
| REF 3 | Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with ... Blood. 2008 Jun 15;111(12):5663-71. | |||
| REF 4 | A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered f... Blood. 2006 Nov 15;108(10):3262-70. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.